Arecor Therapeutics plc
(“Arecor” or the “Group”)
US PATENT GRANTED PROTECTING PROPRIETARY FORMULATIONS OF MONOCLONAL ANTIBODIES
- Endorses potential of proprietary Arestat™ platform technology to invent novel, enhanced therapeutics in $210 billion monoclonal antibody market
- Further strengthens Group’s extensive patent portfolio